177 related articles for article (PubMed ID: 23645688)
21. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
[TBL] [Abstract][Full Text] [Related]
22. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
[TBL] [Abstract][Full Text] [Related]
23. High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome.
Kumar L; Ramavath D; Kataria B; Tiwari A; Raj A; Chellapuram SK; Mookerjee A; Sahoo RK; Malik PS; Sharma A; Gupta R; Sharma OD; Biswas A; Kumar R; Thulkar S;
Indian J Med Res; 2019 Jun; 149(6):730-739. PubMed ID: 31496525
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a retrospective national multi-site cohort study.
Cohen YC; Zuckerman T; Yeshurun M; Perez G; Magen H; Henig I; Levi I; Shargian L; Trestman S; Rouvio U; Naparstek E; Ganon-Elazar E; Avivi I; Ram R
Ann Hematol; 2017 Feb; 96(2):271-278. PubMed ID: 28039512
[TBL] [Abstract][Full Text] [Related]
25. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.
Jacobs RW; Saliba RM; Sasaki K; Farhan S; Armas A; Shah ND; Bashir Q; Qureshi S; Rondon G; Hosing C; Popat U; Parmar S; Shah JJ; Wang M; Weber DM; Thomas SK; Orlowski RZ; Champlin RE; Qazilbash MH
Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):36-42. PubMed ID: 26702475
[TBL] [Abstract][Full Text] [Related]
26. Younger donor's age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
Fabre C; Koscielny S; Mohty M; Fegueux N; Blaise D; Maillard N; Tabrizi R; Michallet M; Socié G; Yakoub-Agha I; Garban F; Uzunov M; François S; Contentin N; Lapusan S; Bourhis JH
Haematologica; 2012 Apr; 97(4):482-90. PubMed ID: 22058218
[TBL] [Abstract][Full Text] [Related]
27. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
[TBL] [Abstract][Full Text] [Related]
28. [Clinical significance of abnormal protein bands in multiple myeloma treated with bortezomib-based induction regimen and autologous stem cell transplantation].
Wang HH; Li J; Liu JR; Zheng D; Gu JL; Yan MS; Zou WY; Xu DR
Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):327-31. PubMed ID: 23668206
[TBL] [Abstract][Full Text] [Related]
29. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients.
Lahuerta JJ; Martinez-Lopez J; Serna JD; Bladé J; Grande C; Alegre A; Vazquez L; García-Laraña J; Sureda A; Rubia JD; Conde E; Martinez R; Perez-Equiza K; Moraleda JM; León A; Besalduch J; Cabrera R; Miguel JD; Morales A; García-Ruíz JC; Diaz-Mediavilla J; San-Miguel J
Br J Haematol; 2000 May; 109(2):438-46. PubMed ID: 10848839
[TBL] [Abstract][Full Text] [Related]
30. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
[TBL] [Abstract][Full Text] [Related]
31. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.
Gahrton G; Iacobelli S; Björkstrand B; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Carella AM; Beksac M; Bosi A; Milone G; Corradini P; Schönland S; Friberg K; van Biezen A; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Garderet L; Kröger N;
Blood; 2013 Jun; 121(25):5055-63. PubMed ID: 23482933
[TBL] [Abstract][Full Text] [Related]
32. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
33. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.
Maffini E; Storer BE; Sandmaier BM; Bruno B; Sahebi F; Shizuru JA; Chauncey TR; Hari P; Lange T; Pulsipher MA; McSweeney PA; Holmberg L; Becker PS; Green DJ; Mielcarek M; Maloney DG; Storb R
Haematologica; 2019 Feb; 104(2):380-391. PubMed ID: 30262560
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT Registry Study. European Group for Bone Marrow Transplantation.
Björkstrand B; Goldstone AH; Ljungman P; Brandt L; Brunet S; Carlson K; Prentice G; Cavo M; Samson D; de Laurenzi A
Leuk Lymphoma; 1994 Oct; 15(3-4):265-72. PubMed ID: 7866274
[TBL] [Abstract][Full Text] [Related]
35. [Observation of humoral immunity reconstitution and its relationship with infection after autologous hematopoietic stem cell transplantation for patients with multiple myeloma].
Liu JR; Li J; Shang JJ; Zheng D; Gu JL; Zou WY; Xu DR
Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):317-22. PubMed ID: 23668204
[TBL] [Abstract][Full Text] [Related]
36. Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation.
Hall SL; Tate J; Gill D; Mollee P
Clin Biochem Rev; 2009 Aug; 30(3):113-8. PubMed ID: 19841693
[TBL] [Abstract][Full Text] [Related]
37. [Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center].
Wu Q; Liu JR; Huang BH; Zou WY; Gu JL; Chen ML; Kuang LF; Zheng D; Xu DR; Zhou ZH; Wang HH; Su C; Tong XZ; Li J
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):453-459. PubMed ID: 31340616
[No Abstract] [Full Text] [Related]
38. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
39. Abnormal protein bands in patients with multiple myeloma after haematopoietic stem cell transplantation: does it have a prognostic significance?
Sucak G; Suyanı E; Özkurt ZN; Yeğin ZA; Aki Z; Yagci M
Hematol Oncol; 2010 Dec; 28(4):180-4. PubMed ID: 20155734
[TBL] [Abstract][Full Text] [Related]
40. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
Krishnan A; Pasquini MC; Logan B; Stadtmauer EA; Vesole DH; Alyea E; Antin JH; Comenzo R; Goodman S; Hari P; Laport G; Qazilbash MH; Rowley S; Sahebi F; Somlo G; Vogl DT; Weisdorf D; Ewell M; Wu J; Geller NL; Horowitz MM; Giralt S; Maloney DG;
Lancet Oncol; 2011 Dec; 12(13):1195-203. PubMed ID: 21962393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
